Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France

About this trial

Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is estimated to affect 0.5 to 2.5% of samples.

This is particularly the case for anti-Xa activity, a critical test used to monitor anticoagulant treatments.

To date, the HUS Hematology Laboratory does not have or is aware of any alternative method to overcome this interference, and is unable to perform anti-Xa activity when the sample has excessive lipemia. This study will evaluate, on samples from routine care artificially overloaded with lipids, the effectiveness of a high-speed centrifugation process (10,800g for 10 minutes).

Eligibility criteria

Qualifiers

Adult patient (≥ 18 years)

Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban)

Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care

Disqualifiers

Patient with a basal lipidemic sample

Sample of insufficient volume

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed